Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Myriad Genetics Inc MYGN

Healthcare Biotechnology
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has... see more

Recent & Breaking News (NDAQ:MYGN)

Myriad's Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes

GlobeNewswire December 14, 2019

Myriad's Prequel(TM) Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening

GlobeNewswire December 4, 2019

Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium

GlobeNewswire December 3, 2019

CLASS ACTION UPDATE for OSTK, MYGN and GRUB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

ACCESSWIRE IA November 26, 2019

FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm

ACCESSWIRE IA November 26, 2019

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SEE, MYGN, ZEN and YJ

GlobeNewswire November 26, 2019

MYGN DEADLINE TODAY: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Myriad Genetics (MYGN) Investors of Today's Deadline to Move for Lead Plaintiff

ACCESSWIRE IA November 26, 2019

FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm

ACCESSWIRE IA November 25, 2019

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of MYGN, CC and ET

ACCESSWIRE IA November 25, 2019

FINAL DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline Tomorrow

ACCESSWIRE IA November 25, 2019

SHAREHOLDER ALERT: MYGN TEUM ACB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

ACCESSWIRE IA November 25, 2019

Myriad Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Myriad Genetics, Inc. To Contact The Firm

Newsfile November 25, 2019

DEADLINE ALERT - Myriad Genetics, Inc. (MYGN) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: November 26, 2019

ACCESSWIRE IA November 25, 2019

MYGN FINAL DEADLINE: ROSEN LAW FIRM Reminds Myriad Genetics, Inc. Investors of Tuesday Deadline in Securities Class Action - MYGN

GlobeNewswire November 25, 2019

CLASS ACTION UPDATE for CVET, MYGN, ZEN and PLT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

GlobeNewswire November 25, 2019

FINAL DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm

ACCESSWIRE IA November 24, 2019

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MYGN, DOMO and PLT

ACCESSWIRE IA November 24, 2019

2-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching

ACCESSWIRE IA November 24, 2019

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm

PR Newswire November 23, 2019

3-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching

ACCESSWIRE IA November 23, 2019